TENAX THERAPEUTICS, INC. Accretion Expense
TENAX THERAPEUTICS, INC. (TENX) reported Accretion Expense of $2.84 million for the 12-month period ending 2012-04-30, per its 10-K filed 2013-06-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2013-06-26
- TENAX THERAPEUTICS, INC. accretion expense for fiscal 2012 was $2.84M.
| Period end | Accretion Expense 12 month |
|---|---|
| 2012-04-30 | $2.84M 10-K · filed 2013-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |